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Locally advanced breast 
cancer (LABC) comprises 
a heterogenous group of 
diseases, which incorporates 
a subset of stage IIB (T3N0) 
disease, stage III disease and inflammatory 
breast cancer (IBC) (Fig. 1). In the developed 
world, based on data from the Surveillance, 
Epidemiology, and End Results (SEER) 
Program of the National Cancer Institute, USA, 
7% of breast cancer patients have stage III 
disease at diagnosis. This is in stark contrast to 
developing countries, where LABC constitutes 
30 - 60% of all cases, probably because of a lack 
of education and poor socioeconomic status. 
SEER data demonstrate a median survival of 4.9 
years, while the 5-year relative survival rate for 
this group of women is 55% with multimodality 
treatment, excluding biologics.[1,2]
IBC is a rare, distinct subtype of breast 
cancer associated with rapid disease 
progression and characterised by erythema 
and dermal oedema (peau d’orange) of a 
third or more of the skin area of the breast, 
with a palpable border to the erythema.[3] 
Initial patient evaluation 
All cases of LABC should ideally be discussed 
by a multidisciplinary team comprising an 
oncologist, a breast surgeon, a radiologist, a 
nurse and a pathologist. 
A detailed history of the presenting 
symptoms, previous breast pathology, risk 
factors for breast cancer, medical and surgical 
comorbidities and, in the pre-menopausal 
female, aspects surrounding family planning 
and fertility, are important. 
This should be followed by a complete 
clinical examination and blood tests, including 
a full blood count, a liver function test and 
alkaline phosphatase levels. Abnormalities in 
the latter two tests may point towards liver 
and bone metastases, respectively. In South 
Africa’s HIV-endemic population group, HIV 
testing is important owing to a higher risk 
of chemotherapy-induced haematological 
toxicities in immunocompromised patients. 
A diagnostic bilateral mammogram (if 
physically possible) and ultrasound imaging, 
as well as a chest radiograph to exclude 
pulmonary metastases, are also part of the 
mandatory work-up.[3] 
Core needle breast biopsy is the 
standard diagnostic procedure as it results 
in minimal tumour perturbation while 
offering important diagnostic information, 
including the identification of tumours that 
are predominantly or completely located in 
situ. Additional information gleaned from 
a core needle biopsy includes the evaluation 
of the necessary prognostic and predictive 
tumour biomarkers, e.g. oestrogen receptor/
progesterone receptor (ER/PR), HER2-neu, 
tumour grade and the Ki67 proliferation 
marker. This is especially important in the 
setting of neoadjuvant chemotherapy (NAC) 
as it may be the only available tumour 
present if subsequent pathological complete 
response (pCR) is achieved.[4]
While the National Comprehensive 
Cancer Network (NCCN) guidelines[3] 
suggest that bone scans and abdominal 
imaging should be directed by symptoms 
and other study results, it is standard 
practice at our institution for patients with 
LABC to undergo an initial isotope bone 
scan to exclude bone metastases and an 
abdominal ultrasound to exclude liver 
metastases. [18F]-fluorodeoxyglucose 
(FDG) positron emission tomography/
computed tomography (PET/CT) is 
primarily used when there are suspicious 
or equivocal findings on standard imaging 
studies. An assessment of the left ventricular 
ejection fraction with an echocardiogram 
or multigated acquisition (MUGA) scan is 
mandatory when considering the use of 





NAC refers to chemotherapy prior to 
surgery and is the current standard of care 
for LABC. It has many potential benefits 
over immediate surgery and postoperative 
adjuvant chemotherapy in the management 
of LABC, which include eradication of 
occult distant micrometastases and down-
staging of a previously unresectable breast 
malignancy to an operable one. Another 
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Fig. 1. Locally advanced carcinoma of the right 
breast.
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advantage of NAC is the opportunity to 
monitor tumour response to therapy.[5,6]
It is noteworthy that, despite the benefits 
associated with the use of NAC, there is no 
difference between disease-free and overall 
survival of patients treated with  this mode 
of chemotherapy compared with adjuvant 
therapy.[6]
Regimens
Historically, regimens based on anthracy-
cline (adriamycin or epirubicin) and cyclo-
phosphamide with or without fluoropyrim-
idines, e.g. 5-deoxyfluorouridine, formed 
the backbone of NAC regimens. Second-
generation trials focused on the addition 
of taxanes (paclitaxel or docetaxel), either 
in combination or used sequentially with 
anthracycline-based regimens. The latter 
demonstrated improved pCR rates and 
avoidance of further postoperative adjuvant 
chemotherapy.[6] 
Based on clinical trial data, unless there 
is clear evidence of disease progression, 
deviations from the planned therapy in 
clinical non-responders do not increase 
pCR or clinical response rate (cRR) 
or improve survival. Therefore, both 
responders and non-responders to four 
cycles of an initial anthracycline-based 
regimen benefit from crossover to non-
cross-resistant therapeutic intervention, 
usually including a taxane. Most of 
the systemic chemotherapy should be 
administered before the local treatment.[1] 
Pathological complete 
response as a predictor 
of survival 
Based on current levels of evidence, pCR 
(ypT0/is, ypN0) has been repeatedly 
confirmed as the most important prognostic 
factor and surrogate marker for longer 
survival in patients receiving NAC. While 
the ideal result for a patient undergoing 
NAC is eradication of the malignancy in the 
breast and the axillary lymph nodes, some 
residual invasive and/or pre-invasive disease 
may be identifiable by the pathologist after 
surgery.[7] 
The residual cancer burden (RCB) may 
be used to assess the remaining disease 
by combining the diameter of the residual 
primary cancer and the cellularity fraction 
of the invasive cancer with the diameter of 
the largest metastasis in the regional lymph 
nodes in a formula called the RCB Index. 
By utilising measurements made on routine 
pathology samples, the RCB Index identifies 
near pCR and subgroups of resistant cancers 
and has been validated as a predictor of 
distant relapse following NAC.[7]
Evaluating 
chemotherapy response 
based on molecular 
subtypes of breast cancer
A clinically relevant molecular classification 
of breast cancer has been introduced, 
incorporating surrogate markers that 
would allow for the identification of 
molecular subtypes using the more familiar 
immunohistochemical approach. The 
combined evaluation of ER/PR, HER2-neu 
and Ki67 immunoreactivity approximates 
the molecular classification of luminal 
A, luminal B, HER2-enriched and triple-
negative breast cancer. This molecular 
classification has prognostic value and is 
also predictive of response to NAC.[8]
In patients with a luminal A biological 
phenotype (ER/PR-positive, HER2-negative, 
and low Ki67), the conventional chemotherapy 
regimens have a 6.7% chance of attaining 
a pCR. The luminal B-type patients (ER/
PR-positive, HER2-neu-negative, high Ki67 
and ER/PR-positive, HER2-neu-positive, any 
Ki67) have an 11 - 22% pCR rate, with poorer 
survival reported in this subset of patients 
when pCR is not achieved. The triple-negative 
(ER/PR-negative, HER2-negative) group of 
breast cancers are a highly proliferative group 
of tumours, representing a very responsive 
group with a 28 - 32% probability of a pCR. A 




Neoadjuvant hormonal therapy (NHT) is 
an effective therapeutic modality for down-
sizing primary tumours and rendering 
them operable, as well as increasing 
conversion rates from mastectomy to breast 
conservation surgery in post-menopausal, 
hormone receptor (HR)-positive breast 
cancer patients. Furthermore, the favourable 
toxicity profile of NHT makes it a very 
suitable treatment option for patients unfit 
for chemotherapy.[9] 
The evidence suggests that NHT has 
comparable response rates to NAC. In post-
menopausal women, aromatase inhibitors 
(AIs) have demonstrated better results than 
tamoxifen. In the majority of studies, the 
duration of NHT use prior to surgery was 
between 3 and 4 months. The available data 
exploring longer treatment duration, using 
NHT longer than 3 - 4 months, demonstrated 
additional clinical responses and further 
tumour down-sizing.[9]
HER2-directed therapies
Approximately 20% of breast cancers 
overexpress the epidermal growth factor 
receptor HER2-neu, providing a prognostic 
and predictive marker for improving pCR 
rates.[5]
In tumours with overexpressed or ampli-
fied HER2, adding trastuzumab (Herceptin) 
to NAC achieves higher pCR rates, mostly 
in combination with anthracyclines 
and taxanes. New data demonstrate that 
combinations of chemotherapy and trastu-
zumab with a second anti-HER2 agent 
(lapatinib, pertuzumab) lead to higher pCR 
rates, which may be translated into a survival 
benefit.[6]
One year of adjuvant trastuzumab remains 
the standard of care after surgery in patients 
with HER2-positive tumours.[10]
Adjuvant radiotherapy
Radiotherapy can usually start within 
2 - 4 weeks of surgery. Patients receiving 
chemotherapy can mostly begin radiotherapy 
3 weeks after the last cycle of chemotherapy.[11]
Whole breast radiotherapy
All patients undergoing breast conservation 
surgery require adjuvant whole breast 
radiotherapy (Fig. 2). The target volume is 
the entire breast using tangential fields treated 
with 45 - 50 Gy in 1.8 - 2 Gy fractions, 
daily from Monday to Friday. A tumour 
bed boost with electrons to 60 - 66 Gy is 
recommended. Both computed tomography 
(CT) scanning and the use of surgical clips 
have been shown to improve accuracy of 
localisation of the tumour volume, tumour 
bed depth and choice of electron energy 
compared with clinical assessment alone.[12] 
Post-mastectomy radiotherapy
Indications for post-mastectomy radiotherapy 
(PMRT) include patients with T3, T4 tumours 
and those with ≥4 positive axillary nodes. In 
patients with 1 - 3 positive axillary nodes, 
locoregional radiotherapy may be considered 
for young patients, large T2 - 3 tumours, grade 
III tumours, ER-negative, lymphovascular 
invasion or lobular histology.[12]  
Fig. 2. Left chest wall radiation therapy. 
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Initial patient work-up
• Detailed history and physical examination
• Bilateral mammography and ultrasound of the breasts
• Tru-cut biopsy of the breast (ER/PR and HER2-neu status, Ki67 index and tumour grade)
• Full blood count, liver function test, HIV enzyme-linked immunosorbent assay (ELISA) 
• Chest X-ray, ultrasound of abdomen, bone scan
• Anthracylines • Usually reserved for HR-positive post-menopausal and 
  HR-positive women who are unfit for chemotheraphy
• Usually administered for 3 - 4 months
• Aromatase inhibitors (AIs) preferred over tamoxifen in 
  post-menopausal women
• Taxanes
• Recommended for all patients after breast conservation surgery/wide local excision
Neoadjuvant chemotherapy with or without trastuzumab Neoadjuvant hormonal therapy
· Common regimen:
  adriamycin, cyclophosphamide (AC);
  epi-adriamycin, cyclophosphamide (EC);
  5-deoxyuorouridine (5-FU), epi-adriamycin, 
  cyclophosphamide (FEC);
  5-FU, epi-adriamycin, cyclophosphamide (FAC)
· Usually 4 cycles given every 3 weeks,
  followed sequentially by taxanes
· Either docetaxel or paclitaxel for 4 cycles
Surgery
Wide local excision and axillary lymph node dissection
or
Total mastectomy and axillary lymph node dissection with or without immediate breast reconstruction
Adjuvant radiotherapy
Whole breast radiotherapy
Post-mastectomy chest wall radiotherapy
• Recommended for tumours ≥5 cm in diameter (T3) and ≥4 axillary nodes involved 
• Select high-risk patient population groups with 1 - 3 axillary nodes involved
Regional lymph node irradiation
Recommended for patients with ≥4 axillary nodes involved 
• Supraclavicular node irradiation
• Axillary node irradiation
Recommended for patients with an incompletely dissected axilla or extracapsular axillary node extension
Adjuvant hormonal therapy in HR-positive patients
Pre-menopausal females
• Tamoxifen for 5 years remains the standard of care
• Extended use of tamoxifen for 10 years may be considered, although compliance and higher 
  risk of endometrial cancer need to be considered
• Ovarian function suppression with tamoxifen is not routinely recommended
Post-menopausal females
• 3 possible treatment strategies
· AIs up-front
· Sequential tamoxifen for 2 - 3 years, followed by AIs for 2 - 3 years, or reverse sequence
· Extended AI use in high-risk patients who have completed 5 years of tamoxifen
• Multigated acquisition (MUGA) scan/echocardiogram to assess left venticular ejection fraction
Not routinely recommended unless clinically involved
• Internal mammary node irradiation
• Trastuzumab
· Docetaxel usually given 3-weekly
· Paclitaxel given either weekly or 3-weekly
· May be combined with neoadjuvant chemotherapy in
  patients with HER2-positive disease
Fig. 3. Proposed treatment algorithm for the management of locally advanced breast cancer.
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Radiotherapy is delivered using opposed tangential fields to 
encompass the ipsilateral chest wall to a dose of 45 - 50 Gy in 
1.8 - 2 Gy fractions, daily from Monday to Friday. 3D CT scan 
planning is recommended to ensure adequate coverage of target, 
while limiting the dose to the lungs and heart.[13]
In a patient who underwent immediate breast reconstruction after 
mastectomy, conformal or intensity modulated radiotherapy (IMRT) 
techniques should be used to optimise homogeneity of dose, and 
bolus irradiation should be avoided if possible to maintain good 
cosmesis.[12]
Regional lymph node irradiation
The risk of microscopic invasion of the supraclavicular lymph 
nodes is largely influenced by the number of involved axillary 
nodes. Supraclavicular lymph node irradiation is indicated when 4 
or more axillary nodes are invaded, usually suggesting a 15 - 20% 
risk of supraclavicular lymph node involvement. With conventional 
fractionation (1.8 - 2 Gy/fraction) to a total dose of 45 - 50 Gy, the 
risk of side-effects remains low.[14]
Axillary nodal irradiation is indicated if the patient has had an 
inadequate axillary dissection, or if there is evidence of extracapsular 
nodal extension. The lateral border of the supraclavicular field 
incorporates the axilla. The axillary and supraclavicular lymph 
node stations are treated using an anterior field with or without a 
posterior axilla boost field to a total dose of 45 - 50 Gy in 1.8 - 2 
Gy fractions.[13]
The incidence of internal mammary node (IMN) involvement varies 
between 3% and 65%, depending on the tumour stage and location 
of the primary tumour in the breast. However, clinically apparent 
invasion of these nodes is only 2%. As for the role of IMN radiotherapy, 
no trial has included sufficient patients or has had sufficient follow-up 
to definitively evaluate the value of IMN irradiation. If obvious clinical 
involvement of the IMN chain is present, the IMN can be encompassed 




The standard adjuvant hormonal therapy in pre-menopausal women 
with ER-positive disease is tamoxifen alone for 5 years, but benefit 
has also been shown with ovarian function suppression (OFS) 
using luteinising hormone-releasing hormone (LHRH) agonists, 
specifically in the absence of chemotherapy. Nonetheless, the use of 
OFS added to chemotherapy, tamoxifen or a combination of both is 
not routinely recommended.[10] 
Post-menopausal women
The AIs, anastrozole, letrozole and exemestane, have been widely 
investigated in the adjuvant setting. These drugs may be used as 
up-front therapy for 5 years, ‘switch’ strategy of initial tamoxifen for 
2 - 3 years, followed by an AI for 2 - 3 years, the reverse sequence, or as 
an extended treatment after 5 years of tamoxifen, especially in node-
positive patients. Because of the heightened risk of osteoporosis with 
AI use, guidelines recommend surveillance of bone mineral density 
during AI treatment, and calcium and vitamin D supplementation, or 
a bisphosphonate, depending on the result.[10]
Extended endocrine therapy
Due to the risk of recurrence in HR-positive disease after the first 
decade, clinicians and researchers have been questioning the benefit 
of extended tamoxifen treatment after 5 years. Three prospective 
trials (NSABP-B14, aTTom and ATLAS trials) addressed this 
question, randomising patients after 5 years of tamoxifen treatment 
to an additional 5 years of treatment or placebo.[10] Except for 
the NSABP-B14 trial, these studies have demonstrated benefit 
for extended tamoxifen usage. However, 10 years of tamoxifen is 
associated with an increased incidence of endometrial cancer (2.3-
fold with 5 years and 4-fold with 10 years of tamoxifen). Tamoxifen 
did, however, show a favourable effect on lipid profile.[10]
It is worthwhile noting that compliance when on hormonal 
treatment is challenging, with reports suggesting that adherence to 
tamoxifen falls to 50% during the course of therapy. Non-adherence 
to anastrozole has been reported in approximately one-third of 
patients. Of patients taking AIs, the main reason for treatment 
discontinuation is musculoskeletal toxicities.[10]
A proposed treatment algorithm for the management of LABC is 
given above (Fig. 3).
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